Abstract

The Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT) is an effort of the European Commission’s Innovative Medicines Initiative that aims to advance methods for pharmacoepidemiology and pharmacovigilence, in partnership with the European Medicines Agency (EMA). The focus is to understand discrepancies between reported outcomes from pharmacoepidemiology studies by studying combinations of drugs and adverse events in several databases, to identify and explore sources of variability that may currently affect drug safety studies.

Mission

The overall objective of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. In order to achieve this overall goal, PROTECT has been designed to develop and validate a set of innovative tools and methods that:
2009 – Project start date (January)
2013 – PROTECT project releases major pharmacovigilance databases (February)
2013 – The PROTECT team launches four-country survey on drug use by pregnant women
2013 – PROTECT releases reviews of benefit-risk methods and their visualization (July)
2014 – IMI published an updated version of the Drug Consumption Databases (February)

Structure & Governance

The PROTECT governance structure is a multi-layer structure comprising three components:

Governance and scientific oversight

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Expertise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helen Dolk, PhD</td>
<td>Professor of Epidemiology at the University of Ulster, UK</td>
<td>Perinatal epidemiology, pharmacoepidemiology</td>
</tr>
<tr>
<td>Trevor Gibbs, MD</td>
<td>Former Head of Global Pharmacovigilance and Product Safety, GSK, UK; Chief Medical Officer at ii4sm</td>
<td>Pharmacovigilance, health outcomes, public health</td>
</tr>
<tr>
<td>David Haerry</td>
<td>European AIDS Treatment Group, Brussels, Belgium</td>
<td>Pharmacoepidemiology</td>
</tr>
<tr>
<td>Vicky Hogan, PhD</td>
<td>Director, Office of Risk Management and Science, Marketed Health Products Directorate, Health Canada</td>
<td>Benefit-risk assessment</td>
</tr>
<tr>
<td>Michael Lewis, MD</td>
<td>EPES Epidemiology, Pharmacoepidemiology and Systems Research GmbH, Berlin, Germany</td>
<td>Pharmacoepidemiology</td>
</tr>
<tr>
<td>Allen Mitchell, MD</td>
<td>Slone Epidemiology Center, Boston, USA</td>
<td>Perinatal epidemiology, pharmacoepidemiology</td>
</tr>
<tr>
<td>Marcus Müllner, MD</td>
<td>Head of AGES PharmMed (Austrian Medicines and Medical Devices Agency), Austria</td>
<td>Benefit-risk assessment, clinical epidemiology, pharmacovigilance</td>
</tr>
<tr>
<td>Gerald Dal Pan, M.D., M.H.S.</td>
<td>Director, Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug</td>
<td>Pharmacovigilance, drug development, public health,</td>
</tr>
</tbody>
</table>
The Steering Committee has the central role in the governance structure and the management of the project. The Steering Committee includes all Work Package co-Leaders, the coordinator, the deputy coordinator, and their alternates.

During the initiation phase of the project, the Steering Committee will in principle meet every month. In the following years, the Steering Committee will meet at least four times annually.

Main roles and responsibilities:

- Finalization and approval of the PROTECT Management Plan,
- Decisions for the initiation and execution of the activities included in the Project Management Plan,
- Approval of the budget allocation to Work Package members and the in-kind contribution from private partners,
- Review of the progress and of the quality control findings of the work program,
- Discussion of recommendations proposed by the External Advisory Board and the Consortium Assembly,
- Decisions regarding communication and dissemination of the project deliverables,
- Discussion of problems and conflicts that may arise during the course of the program when these have not been solved by the coordinator and the deputy coordinator, and
- Decisions regarding the admission of new partners from the Extended Audience.
The coordinator is responsible for the successful management and delivery of the project. He is the contact point for discussions with the IMI JU and is in charge of the execution of the work plan with the Work Package co-leaders and of the implementation of the decisions taken by the Steering Committee. The coordinator is responsible for the overall governance of PROTECT.

The deputy coordinator has three main roles: to coordinate the input (scientific and in-kind) from the private consortium (i.e., industry partners), to support the coordinator with the development and implementation of the Project Management Plan and delivery of outcomes, and to support the coordinator with governance of PROTECT and be involved in decision-making for the project.

<table>
<thead>
<tr>
<th>Work Package</th>
<th>Co-Leaders</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>WP1</td>
<td>Xavier Kurz</td>
<td>EMA</td>
</tr>
<tr>
<td></td>
<td>Elizabeth Swain</td>
<td>GSK</td>
</tr>
<tr>
<td>WP2</td>
<td>Olaf Klungel</td>
<td>UU</td>
</tr>
<tr>
<td></td>
<td>Robert Reynolds</td>
<td>Pfizer</td>
</tr>
<tr>
<td>WP3</td>
<td>Niklas Norén</td>
<td>UMC</td>
</tr>
<tr>
<td></td>
<td>Michael Kayser</td>
<td>Bayer</td>
</tr>
<tr>
<td>WP4</td>
<td>Omer de Mol</td>
<td>Genzyme</td>
</tr>
<tr>
<td>WP5</td>
<td>Deborah Ashby</td>
<td>Imperial</td>
</tr>
<tr>
<td></td>
<td>Alain Micaleff</td>
<td>ME</td>
</tr>
<tr>
<td>WP6</td>
<td>Lucien Abenhaim</td>
<td>PGRx(LASER)</td>
</tr>
<tr>
<td></td>
<td>Laurent Auclert</td>
<td>SARD</td>
</tr>
<tr>
<td>WP7</td>
<td>Joan-Ramon Laporte</td>
<td>FICF</td>
</tr>
<tr>
<td></td>
<td>Elena Rivero</td>
<td>Novartis Pharma</td>
</tr>
</tbody>
</table>

Members of the Extended Audience are European centers that have established or have access to specific clinical trial data, patient registries, cohorts, or case-control resources, or individuals with expertise in specific domains to be addressed by WP6 (pharmacology, clinical expertise, pharmacoepidemiology).

**Financing**

This project is funded by the Innovative Medicines Initiative, a public-private partnership between the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), resources of which are composed of financial contributions from the EU Seventh Framework.
Programme and EFPIA companies’ in-kind contributions. Large pharmaceutical companies participating in IMI projects do not receive IMI funding.

The IMI Intellectual Property (IP) Policy governs the IP regime of all projects funded by the IMI JU. To assist with specific IP queries, IMI has set up a dedicated IP Helpdesk that can be contacted by e-mailing IMI-IP-Helpdesk@imi.europa.eu. The IMI IP policy can be accessed at the following address: http://www.imi.europa.eu/sites/default/files/uploads/documents/imi-ipr-policy01august2007_en.pdf

**Patent Engagement**

Collection of data directly from patients is essential in many situations. PROTECT will direct patient data collection in natural languages using Web-based, telephone and text messaging systems. It will test the transferability of the data into a common language and explore linkages to data from electronic health records and registries.

The PROTECT project will enhance the monitoring of the safety of medicinal products. It will also contribute to better evaluating and communicating their benefit-risk profile throughout their lifecycle. To this end, innovative tools and methodological standards will be developed.

**Homepage**
http://www.imi-protect.eu/

**Other website**
http://www.imi.europa.eu/content/protect

**Twitter**
https://twitter.com/PROTECT_BR

**Data Sharing**

According to IMI’s intellectual property policy, the participants undertake to disseminate the data as soon as reasonably practicable but not later than one year after the termination or expiry of the project. The Project Agreement shall include a description of the material that must be disseminated in accordance with the IP Policy and referenced in the Grant Agreement. If the participants do not disseminate within such time periods without good reason, the Executive Office has the right to disseminate such results in a manner consistent with the Grant Agreement.

**Points of Contact**
Xavier Kurz  
European Medicines Agency  
Pharmacovigilance and Risk Management  
London  
United Kingdom

Elizabeth Swain  
GlaxoSmithKline Research and Development LTD,  
Harlow  
United Kingdom

Per Helboe  
Danish Medicines Agency, Licensing Division  
Copenhagen  
Denmark

Sponsors & Partners

GlaxoSmithKline Research and Development LTD, Brentford, UK  
Amgen NV, Brussels, Belgium  
Bayer Schering Pharma AG, Berlin, Germany  
AstraZeneca AB, Södertälje, Sweden  
Genzyme Europe B.V., Naarden, The Netherlands  
H. Lundbeck A/S, Valby, Denmark  
Merck KGaA, Darmstadt, Germany  
Novartis Pharma AG, Basel, Switzerland  
Novo Nordisk A/S, Bagsvaerd, Denmark  
Pfizer Limited, Sandwich, United Kingdom  
F. Hoffmann-La Roche AG, Basel, Switzerland  
Sanofi-Aventis Research and Development, Chilly-Mazarin, France
European Medicines Agency
Lægemiddelstyrelsen (Danish Medicines Agency) Copenhagen, Denmark
Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain
Fundación Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain
Fundació Institut Català de Farmacologia, Barcelona, Spain
International Alliance of Patients’ Organizations, London, UK
Imperial College of Science, Technology & Medicine, London, UK
Institut National de la Santé et de la Recherche Médicale, Paris, France
Ludwig-Maximilians-Universität München, München, Germany
Mario Negri Institute for Pharmacological Research, Milan, Italy
Medicines and Healthcare Products Regulatory Agency, London, UK
Rijksuniversiteit Groningen, Groningen, The Netherlands
Stiftelsen WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden
University of Newcastle upon Tyne, Newcastle upon Tyne, UK
Universiteit Utrecht, Utrecht, The Netherlands
LA Santé Épidémiologie Evaluation Recherche, Paris, France
Outcome Europe Sarl, St. Prex, Switzerland

Updated: 04/08/2016